Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 09-Aug-24 4:30 PM View:  | Invus Public Equities, Lp 10% Owner | Glycomimetics Inc (GLYC) | 08-Aug-24 | Sale | 260,873 | $0.19 | $50,009.40 | (4%) 6.58M to 6.32M | |
| 09-Aug-24 4:30 PM View: | Invus Public Equities, Lp 10% Owner | Glycomimetics Inc (GLYC) | 07-Aug-24 | Sale | 61,488 | $0.18 | $11,197.00 | (< 1%) 6.64M to 6.58M | |
| 07-Aug-24 4:30 PM View: | Invus Public Equities, Lp 10% Owner | Glycomimetics Inc (GLYC) | 06-Aug-24 | Sale | 55,732 | $0.18 | $10,187.80 | (< 1%) 6.7M to 6.64M | |
| 07-Aug-24 4:30 PM View: | Invus Public Equities, Lp 10% Owner | Glycomimetics Inc (GLYC) | 05-Aug-24 | Sale | 164,523 | $0.19 | $30,996.10 | (2%) 6.86M to 6.7M | |
| 05-Aug-24 4:53 PM View: | Invus Public Equities, Lp 10% Owner | Glycomimetics Inc (GLYC) | 02-Aug-24 | Sale | 286,200 | $0.20 | $57,354.50 | (4%) 7.15M to 6.86M | |
| 05-Aug-24 4:53 PM View: | Invus Public Equities, Lp 10% Owner | Glycomimetics Inc (GLYC) | 01-Aug-24 | Sale | 63,564 | $0.22 | $13,742.50 | (< 1%) 7.21M to 7.15M | |
| 30-Jul-24 5:16 PM View: | Invus Public Equities, Lp 10% Owner | Glycomimetics Inc (GLYC) | 30-Jul-24 | Sale | 756,835 | $0.22 | $167,185.00 | (9%) 7.97M to 7.21M | |
| 30-Jul-24 5:16 PM View: | Invus Public Equities, Lp 10% Owner | Glycomimetics Inc (GLYC) | 29-Jul-24 | Sale | 363,949 | $0.24 | $85,637.20 | (4%) 8.33M to 7.97M | |
| 30-Jul-24 5:16 PM View: | Invus Public Equities, Lp 10% Owner | Glycomimetics Inc (GLYC) | 26-Jul-24 | Sale | 258,335 | $0.24 | $62,439.60 | (3%) 8.59M to 8.33M | |
| 24-Jun-24 4:29 PM View: | Rock Edwin Chief Medical Officer | Glycomimetics Inc (GLYC) | 21-Jun-24 | Purchase | 115,000 | $0.27 | $30,716.50 | 20% 565.4K to 680.4K | |
| 24-Jun-24 4:29 PM View: | Rock Edwin Chief Medical Officer | Glycomimetics Inc (GLYC) | 20-Jun-24 | Private Purchase | 190,000 | $0.25 | $48,108.00 | 51% 375.4K to 565.4K | |
| 20-Jun-24 4:15 PM View: | Hahn Brian M. SVP Finance, CFO | Glycomimetics Inc (GLYC) | 18-Jun-24 | Private Purchase | 17,500 | $0.25 | $4,334.75 | 33% 53.14K to 70.64K | |
| 02-Apr-24 4:05 PM View: | Junius Daniel M Director | Glycomimetics Inc (GLYC) | 29-Mar-24 | Grant | 5,209 | $3.00 | $15,627.00 | 6% 93.25K to 98.46K | |
| 02-Apr-24 4:05 PM View: | King Rachel K. Director | Glycomimetics Inc (GLYC) | 29-Mar-24 | Grant | 3,334 | $3.00 | $10,002.00 | < 1% 655.76K to 659.1K | |
| 02-Apr-24 4:05 PM View: | Goldberg Mark Alan Director | Glycomimetics Inc (GLYC) | 29-Mar-24 | Grant | 4,584 | $3.00 | $13,752.00 | 14% 31.74K to 36.33K | |
| 02-Jan-24 4:05 PM View: | King Rachel K. Director | Glycomimetics Inc (GLYC) | 29-Dec-23 | Grant | 4,238 | $2.36 | $10,001.70 | < 1% 653.26K to 657.5K | |
| 02-Jan-24 4:05 PM View: | Andrews Patricia S Director | Glycomimetics Inc (GLYC) | 29-Dec-23 | Grant | 5,191 | $2.36 | $12,250.80 | 10% 53.42K to 58.61K | |
| 02-Jan-24 4:05 PM View: | Goldberg Mark Alan Director | Glycomimetics Inc (GLYC) | 29-Dec-23 | Grant | 5,827 | $2.36 | $13,751.70 | 22% 25.91K to 31.74K | |
| 03-Oct-23 4:05 PM View: | Andrews Patricia S Director | Glycomimetics Inc (GLYC) | 30-Sep-23 | Grant | 8,167 | $1.50 | $12,250.50 | 18% 45.25K to 53.42K | (11%) |
| 03-Oct-23 4:15 PM View: | Goldberg Mark Alan Director | Glycomimetics Inc (GLYC) | 30-Sep-23 | Grant | 9,167 | $1.50 | $13,750.50 | 55% 16.75K to 25.91K | (11%) |
| 03-Oct-23 4:05 PM View: | King Rachel K. Director | Glycomimetics Inc (GLYC) | 30-Sep-23 | Grant | 6,667 | $1.50 | $10,000.50 | 1% 646.6K to 653.26K | (11%) |
| 25-Sep-23 4:21 PM View: | Rock Edwin Chief Medical Officer | Glycomimetics Inc (GLYC) | 22-Sep-23 | Market Purchase | 30,403 | $1.38 | $41,956.10 | 9% 345.0K to 375.4K | (4%) |
| 25-Sep-23 4:21 PM View: | Rock Edwin Chief Medical Officer | Glycomimetics Inc (GLYC) | 21-Sep-23 | Market Purchase | 35,000 | $1.38 | $48,300.00 | 11% 310.0K to 345.0K | (4%) |
| 02-Jun-23 4:10 PM View: | Koenig Scott Director | Glycomimetics Inc (GLYC) | 01-Jun-23 | Option Exercise | 21,000 | $0.60 | $12,600.00 | 133% 15.75K to 36.75K | |
| 18-May-23 4:27 PM View: | Hahn Brian M. SVP Finance, CFO | Glycomimetics Inc (GLYC) | 17-May-23 | Private Sale | 3,700 | $1.95 | $7,215.00 | (7%) 56.84K to 53.14K | |
| 11-May-23 5:08 PM View: | Junius Daniel M Director | Glycomimetics Inc (GLYC) | 10-May-23 | Purchase | 30,000 | $1.56 | $46,800.00 | 47% 63.25K to 93.25K | |
| 09-May-23 5:00 PM View: | Johnson Bruce S SVP & Chief Commercial Officer | Glycomimetics Inc (GLYC) | 08-May-23 | Purchase | 13,500 | $1.57 | $21,195.00 | 11% 125.48K to 138.98K | |
| 28-Feb-23 10:00 PM View: | Invus Public Equities, Lp 10% Owner | Glycomimetics Inc (GLYC) | 24-Feb-23 | Purchase | 100,000 | $1.70 | $170,000.00 | 1% 8.49M to 8.59M | |
| 23-Feb-23 6:23 PM View: | Invus Public Equities, Lp 10% Owner | Glycomimetics Inc (GLYC) | 23-Feb-23 | Purchase | 200,000 | $1.75 | $350,760.00 | 2% 8.29M to 8.49M | |
| 23-Feb-23 6:23 PM View: | Invus Public Equities, Lp 10% Owner | Glycomimetics Inc (GLYC) | 22-Feb-23 | Purchase | 150,000 | $1.79 | $268,995.00 | 2% 8.14M to 8.29M | |
| 23-Feb-23 6:23 PM View: | Invus Public Equities, Lp 10% Owner | Glycomimetics Inc (GLYC) | 21-Feb-23 | Purchase | 50,000 | $1.85 | $92,500.00 | < 1% 8.09M to 8.14M | |
| 17-Feb-23 5:29 PM View: | Invus Public Equities, Lp 10% Owner | Glycomimetics Inc (GLYC) | 17-Feb-23 | Purchase | 200,000 | $1.71 | $341,000.00 | 3% 7.89M to 8.09M | |
| 17-Feb-23 5:29 PM View: | Invus Public Equities, Lp 10% Owner | Glycomimetics Inc (GLYC) | 16-Feb-23 | Purchase | 315,266 | $1.68 | $531,129.00 | 4% 7.57M to 7.89M | |
| 17-Feb-23 5:29 PM View: | Invus Public Equities, Lp 10% Owner | Glycomimetics Inc (GLYC) | 15-Feb-23 | Purchase | 1,000,000 | $2.16 | $2,155,800.00 | 15% 6.57M to 7.57M | |
| 13-Feb-23 5:45 PM View: | Invus Public Equities, Lp 10% Owner | Glycomimetics Inc (GLYC) | 09-Feb-23 | Purchase | 11,451 | $3.24 | $37,123.00 | < 1% 6.56M to 6.57M | |
| 30-Jan-23 4:13 PM View: | Koenig Scott Director | Glycomimetics Inc (GLYC) | 27-Jan-23 | Option Exercise | 10,500 | $2.55 | $26,775.00 | 200% 5.25K to 15.75K | |
| 27-Jan-23 5:15 PM View: | Sandell Scott D 10% Owner | Glycomimetics Inc (GLYC) | 26-Jan-23 | Sale | 3,000,000 | $3.12 | $9,356,400.00 | (38%) 7.97M to 4.97M | |
| 27-Jan-23 5:15 PM View: | Sandell Scott D 10% Owner | Glycomimetics Inc (GLYC) | 25-Jan-23 | Private Sale | 652,016 | $3.26 | $2,128,120.00 | (8%) 8.62M to 7.97M | |
| 06-Jan-23 6:35 PM View: | Sandell Scott D 10% Owner | Glycomimetics Inc (GLYC) | 05-Jan-23 | Private Sale | 71,362 | $2.76 | $196,859.00 | (< 1%) 8.69M to 8.62M | |
| 04-Jan-23 5:26 PM View: | Sandell Scott D 10% Owner | Glycomimetics Inc (GLYC) | 04-Jan-23 | Sale | 101,984 | $2.91 | $296,743.00 | (1%) 8.79M to 8.69M | |
| 04-Jan-23 5:26 PM View: | Sandell Scott D 10% Owner | Glycomimetics Inc (GLYC) | 03-Jan-23 | Sale | 174,814 | $2.99 | $522,711.00 | (2%) 8.97M to 8.79M | |
| 04-Jan-23 5:26 PM View: | Sandell Scott D 10% Owner | Glycomimetics Inc (GLYC) | 30-Dec-22 | Private Sale | 121,335 | $3.02 | $366,432.00 | (1%) 9.09M to 8.97M | |
| 27-Dec-22 6:41 PM View: | Rock Edwin Chief Medical Officer | Glycomimetics Inc (GLYC) | 22-Dec-22 | Purchase | 110,000 | $2.25 | $247,500.00 | 55% 200.0K to 310.0K | |
| 18-Nov-22 4:01 PM View: | Junius Daniel M Director | Glycomimetics Inc (GLYC) | 17-Nov-22 | Purchase | 20,000 | $1.87 | $37,400.00 | 46% 43.25K to 63.25K | |
| 16-Nov-22 4:26 PM View: | Rock Edwin Chief Medical Officer | Glycomimetics Inc (GLYC) | 15-Nov-22 | Purchase | 100,000 | $1.66 | $166,000.00 | 100% 100.0K to 200.0K | |
| 16-Nov-22 4:26 PM View: | Rock Edwin Chief Medical Officer | Glycomimetics Inc (GLYC) | 14-Nov-22 | Market Purchase | 100,000 | $1.43 | $143,000.00 | 100% 0 to 100.0K | (7%) |
| 14-Nov-22 4:13 PM View: | Semerjian Harout Chief Executive Officer Director | Glycomimetics Inc (GLYC) | 11-Nov-22 | Market Purchase | 25,000 | $1.29 | $32,250.00 | 100% 0 to 25.0K | 3% |
| 14-Nov-22 4:14 PM View: | Pearson Timothy R Director | Glycomimetics Inc (GLYC) | 11-Nov-22 | Market Purchase | 19,400 | $1.29 | $25,026.00 | 370% 5.25K to 24.65K | 3% |
| 14-Nov-22 4:11 PM View: | Magnani John L. SVP of Research, CSO | Glycomimetics Inc (GLYC) | 11-Nov-22 | Private Purchase | 45,045 | $1.17 | $52,702.60 | 14% 325.88K to 370.92K | |
| 14-Nov-22 4:04 PM View: | Girard Armand SVP, Chief Business Officer | Glycomimetics Inc (GLYC) | 11-Nov-22 | Private Purchase | 6,500 | $1.05 | $6,825.00 | 29% 22.66K to 29.16K |
